Sponsors (34)
The bill aims to lower some Medicare Part B out-of-pocket costs and bolster the Part B trust fund by imposing manufacturer rebates and standardizing payment rules, but it risks pushing higher list prices, leaving substantial cost-sharing for expensive therapies, and adding administrative burdens.
Medicare beneficiaries will pay lower out-of-pocket coinsurance for certain Part B drugs because coinsurance is tied to MFP+6, reducing patient drug costs for those therapies.
Additional manufacturer rebate revenue is directed into the Medicare Part B trust fund, which could lower federal program net costs and help support Medicare Part B solvency.
Removes a special-case carve-out and aligns Part B payment methodology across drugs, increasing payment consistency and reducing complexity for CMS and provider billing.
Manufacturers must remit substantial quarterly rebates, a change that could incentivize higher drug list prices, reduce product availability, or delay introductions of drugs for Medicare patients.
Some Medicare beneficiaries will still face 20% coinsurance based on MFP+6 for expensive therapies, so significant out-of-pocket spending may persist for high-cost drugs.
New reporting and enforcement requirements increase compliance costs for manufacturers, CMS, and GSA (FSS), which could be shifted to payors or consumers and add administrative burden.
Based on analysis of 2 sections of legislative text.
Subjects selected Medicare Part B drugs to ASP+6, institutes quarterly manufacturer rebates tied to MFP negotiations, and sets beneficiary coinsurance using an MFP+6 benchmark with a cap.
Introduced July 7, 2025 by Gregory Francis Murphy · Last progress July 7, 2025
Removes a payment exception that let certain negotiated drugs escape standard Medicare Part B pricing and instead subjects those "selected" drugs to the usual ASP+6 payment method. It also creates a new quarterly reporting and manufacturer rebate requirement tied to drugs covered by the Maximum Fair Price (MFP) negotiation program, and sets beneficiary coinsurance for those drugs based on an "MFP+6" benchmark with an inflation/rebate-related cap.